GE HealthCare has announced the launch of CleaRecon DL, an AI-powered 3D reconstruction technology designed to enhance the quality of cone-beam computed tomography (CBCT) images. This new solution aims to address one of the most significant challenges in interventional radiology: the degradation of CBCT image quality due to streak artifacts caused by the pulsatile nature of blood flow and variations in contrast distribution. CleaRecon DL recently received U.S. FDA 510(k) clearance and the CE mark, making it available for use on the Allia™ platform. CBCT is widely used in interventional suites to provide detailed cross-sectional images during various procedures. However, the presence of artifacts has often limited its effectiveness, reducing the clarity and accuracy of the images. These issues can affect clinicians' confidence in interpreting the images and, consequently, its routine adoption in clinical practice. Despite these limitations, CBCT remains a valuable tool due to its ability to provide comprehensive visualizations of anatomical structures, enhancing procedural accuracy. Arnaud Marie, General Manager of Interventional Solutions at GE HealthCare, emphasized the importance of CleaRecon DL. "The introduction of CleaRecon DL represents a significant advancement in the interventional suite and for CBCT technology," he stated. "By significantly improving image quality and reducing artifacts, this technology empowers clinicians to perform procedures with greater precision and confidence, ultimately leading to better patient outcomes." CleaRecon DL uses deep-learning algorithms, a form of AI that excels in image processing and has been trained on extensive datasets and validated by clinical experts. Clinical validation testing has shown promising results, with 98% of CBCT images reconstructed using CleaRecon DL reported to be clearer than conventional images. Additionally, the technology improved image interpretation confidence in 94% of cases. This enhancement means that healthcare professionals can make more informed decisions, reducing the need for additional imaging and improving the overall efficiency and accuracy of the procedures. Dr. Charles Nutting, an Interventional Radiologist at Image Guided Therapy in Denver, Colorado, provided a firsthand perspective on the technology. "CleaRecon DL elevates CBCT to a new standard, allowing us to confidently use it across a variety of clinical scenarios," he noted. "It reduces the need for manual image manipulation and eliminates artifacts that have traditionally compromised image clarity, thus enhancing our ability to perform precise interventions and provide better patient care." CleaRecon DL is compatible with the Allia IGS 5 and Allia IGS 7 systems and requires an AW workstation with Volume Viewer. The technology will be demonstrated at the Global Embolization Symposium & Technologies (GEST) 2025 Annual Meeting, scheduled for May 15-18, 2025, in New York. This showcase will give healthcare professionals the opportunity to see the technology in action and understand its potential benefits for interventional procedures. The development and deployment of CleaRecon DL reflect GE HealthCare's ongoing commitment to innovation in medical technology. The company aims to improve hospital efficiency, clinical effectiveness, and patient outcomes through advanced solutions like this. Founded over 125 years ago, GE HealthCare is a leading global provider of healthcare solutions, including imaging systems, advanced visualization tools, patient care solutions, and pharmaceutical diagnostics. With a $19.7 billion valuation and a workforce of approximately 53,000, the company is dedicated to advancing personalized, connected, and compassionate care. Industry insiders commend the launch of CleaRecon DL, highlighting its potential to revolutionize interventional radiology. The integration of AI in medical imaging has been a growing trend, and CleaRecon DL represents a significant step forward. Not only does it enhance the image quality, but it also streamlines the workflow, making it easier for clinicians to use CBCT in a wide range of procedures. The technology's availability in the U.S. and EU markets signifies a major milestone in the advancement of interventional imaging capabilities, and it is expected to drive further adoption and improvements in the field. For more information on CleaRecon DL, interested parties can visit GE HealthCare's official website: https://www.gehealthcare.com/products/image-guiding-solutions/cone-beam-computed-tomography. GE HealthCare continues to lead the way in healthcare innovation, with a focus on creating technologies that make healthcare more accessible and effective for all.